<DOC>
	<DOCNO>NCT01627197</DOCNO>
	<brief_summary>Effect adjuvant intra-arterial chemotherapy control tumor progression patient cystectomized locally advanced bladder cancer .</brief_summary>
	<brief_title>Adjuvant Intraarterial Chemotherapy Following Surgery Treat Locally Advanced Bladder Cancer</brief_title>
	<detailed_description>For locally advanced bladder cancer patient , tumor relapse rate radial cystectomy even high 50 % -62 % .Five-year disease-specific survival OS rate organ-confined disease ( defined ≤pT3a ) 78.9 % 68 % , respectively . For non-organ-confined disease ( define pT3b high ) , rate 36.8 % 30.3 % , respectively.Systemic chemotherapy prolong survival 14.8 month , although multiple severe adverse effect , neutrocytopenia , infection/sepsis , renal dysfunction , mucositis , gastrointestinal toxicity . Additionally , mortality rate associate systemic chemotherapy 1 % -4 % .Therefore , objective study determine adjuvant intra-arterial chemotherapy GC able reduce systemic drug toxicity yield well clinical outcome .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Pathologically confirm localized invasive bladder cancer follow standardize radical cystectomy . Transitional cell carcinoma bladder , stage pT34 , N13 , M0.Transitional cell carcinoma may without squamous cell carcinoma and/or adenocarcinoma component . Male female , 18 year age old , estimate life expectancy ≥ 6 month . ECOG performance status 0 1 . Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 x upper limit normal ( ULN ) .Total serum bilirubin≤ 1.5 x upper limit normal ( ULN ) . Absolute neutrophil count ( ANC ) ≥ 1500/μL Platelets ≥ 75,000/μL Hemoglobin ≥ 8.0 g/dL White blood cell count ≥ 3500/μL Creatinine clearance rate , Ccr ≥ 40ml/min Cardiac function level 0~2 . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Bladder cancer without transitional cell carcinoma component , adenocarcinoma , squamous cell carcinoma , small cell carcinoma Evidence distant metastasis beyond pelvis . No definitely pathological stage , pathologic examination perivesical fat , unable differentiate pT2 pT3 , perform lymph node dissection regional lymph node assess dissected lymph node number less ten . Prior neoadjuvant chemotherapy ( systemic intraarterial ) three month preoperatively , include intravesical infusion chemotherapy . Prior pelvic radiation therapy dosage ≥ 30Gy six month preoperatively . Serious liver kidney dysfunction . Accompanied serious disease . Severe/unstable angina , arrhythmia , symptomatic heart failure , hypertension control medication 6 month myocardial infarction . Noncompliance regular followup due psychological , social , family geographical reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Effects Chemotherapy</keyword>
</DOC>